Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Browsing Tag

IgA nephropathy

11 posts
NNovartis
Novartis (SWX:NOVN) Wins Full FDA Nod For Fabhalta And Wider EU Itvisma Use
Read More

Novartis (SWX:NOVN) Wins Full FDA Nod For Fabhalta And Wider EU Itvisma Use

  • 2026-07-17
Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. Novartis…
NNovartis
Novartis reports positive results from Phase III ALIGN trial for IgAN
Read More

Novartis reports positive results from Phase III ALIGN trial for IgAN

  • 2026-06-05
Novartis has announced final results from the Phase III ALIGN study, highlighting that Vanrafia (atrasentan) slows kidney function…
NNovartis
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Read More

Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years

  • 2026-06-05
Novartis Pharma AG Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with…
NNovartis
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Read More

Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years

  • 2026-06-04
Novartis Pharma AG Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with…
NNovartis
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Read More

Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years

  • 2026-06-04
Novartis Pharma AG Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with…
NNovartis
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Read More

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

  • 2026-06-03
Novartis Pharma AG Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented…
NNovartis
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Read More

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

  • 2026-05-27
Novartis Pharma AG Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented…
NNovartis
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Read More

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

  • 2026-05-26
Novartis Pharma AG Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented…
NNovartis
Assessing Novartis (SWX:NOVN) Valuation After Positive Phase III Data And Upcoming Regulatory Milestones
Read More

Novartis Fabhalta Data Sharpens IgA Nephropathy Outlook And Valuation Case

  • 2026-04-07
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…
NNovartis
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Read More

Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%

  • 2026-03-29
Novartis Pharma AG Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study1 40.7% of…
NNovartis
Novartis Expands AI Research Footprint As Kisqali Access Progresses In Canada
Read More

Novartis Advances Kidney Drug And Radioligand Pipeline With Key Milestones

  • 2026-02-18
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…
Switzerland
www.europesays.com